- Nineteen prisoners use cutlery to break out of cells at Winchester prison
- France wants progress in Ukraine before Russia returns to G7
- Italy president begins talks to seek way out of government crisis
- Italian PM expected to resign as political chaos deepens
- Russia says US cruise missile test ‘regrettable’
- Kremlin - No date set for Normandy talks on Ukraine despite Macron meeting
- Egypt court hands out 6 death sentences on terror charges
- Putin says Russian nuclear explosion poses no threat
- Russian panel eyes alleged foreign interference in protests
- Gran Canaria wildfire triggers evacuation of thousands of people
- PM Johnson calls on Germany and France to compromise on Brexit
- Sudan's ex-president Bashir arrives at corruption trial
TEHRAN, September 26 -Merck & Co Inc’s (MRK.N) Kenneth Frazier will stay on as chief executive beyond 2019, the drugmaker said on Wednesday, after it scrapped a policy requiring its CEO to retire at the age of 65.
TEHRAN, Young Journalists Club (YJC) -Merck & Co Inc’s (MRK.N) Kenneth Frazier will stay on as chief executive beyond 2019, the drugmaker said on Wednesday, after it scrapped a policy requiring its CEO to retire at the age of 65.
“CEO succession has been our top priority, and removing the mandatory retirement policy enables the Board to make the best decision concerning the timing of that transition,” Merck’s lead director Leslie Brun said.
Frazier, who turns 65 in December 2019, was named Merck’s CEO in 2011. The company’s stock price has nearly doubled since then.
Under Frazier, Merck has also seen its cancer immunotherapy Keytruda rake in blockbuster sales and become one of the leading products in a new generation of oncology treatments.
Source:Reuters
Your Comment